Drugs / Glembatumumab Vedotin
Trials 11
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03473691 | May 2018 | triple-negative breast carcinoma | University of Virginia | Withdrawn | No outcome recorded Stop: Business |
| Phase 1/24 trials · 1 met primary | ||||||
| Phase 1/2 | NCT03326258 | Apr 2018 | cutaneous melanoma, metastatic malignant neoplasm, metastatic melanoma, phosphoglycoprotein 1 +2 | National Cancer Institute (NCI) | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT02713828 | Apr 2016 → May 2018 | squamous cell lung carcinoma | PrECOG, LLC. | Terminated | No outcome recorded |
| Phase 1/2 | NCT00704158 | Jun 2008 → Nov 2010 | breast cancer | CuraGen Corporation | Completed | Met primary |
| Phase 1/2 | NCT00412828 | Jun 2006 → Dec 2010 | metastatic melanoma | CuraGen Corporation | Completed | No outcome recorded |
| Phase 25 trials · 2 missed | ||||||
| Phase 2 | NCT02487979 | Feb 2016 → Jun 2017 | osteosarcoma | National Cancer Institute (NCI) | Completed | Missed primary |
| Phase 2 | NCT02363283 | Sep 2015 → Jul 2018 | uveal melanoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT02302339 | Nov 2014 → Jun 2018 | melanoma | Celldex Therapeutics | Terminated | No outcome recorded |
| Phase 2 | NCT01997333 | Nov 2013 → Nov 2017 | triple-negative breast carcinoma | Celldex Therapeutics | Completed | Missed primary |
| Phase 2 | NCT01156753 | Jul 2010 → Oct 2012 | breast cancer | Celldex Therapeutics | Completed | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT03067935 | — | triple-negative breast carcinoma | Celldex Therapeutics | No longer available | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | glembatumumab vedotin | “CDX-011 (glembatumumab vedotin, an antibody-drug conjugate)” NCT01997333 ↗ |
| Known as | CDX-011 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01156753 ↗ |
| Known as | CR011-vcMMAE | “A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (The METRIC Study)” NCT01997333 ↗3“A Phase II, Randomized, Multicenter Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer” NCT01156753 ↗ |
| Known as | Glembatumumab vedotina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1743028 ↗ |
| Known as | Glembatumumab vedotine | ChEMBL registry synonym — accepted as the source's own label CHEMBL1743028 ↗ |
| Action | Deplete | “can lead to cell death of the targeted cell” NCT02302339 ↗ |
| Modality | Other / unclassified | “an Anti-gpNMB Antibody-drug Conjugate” NCT02302339 ↗ |
| Route | Intravenous | “intravenous infusion” NCT00412828 ↗ |
| Target | GPNMB | “GPNMB” NCT02302339 ↗ |